Febufast 40

Febufast 40

febuxostat

Manufacturer:

ACME

Distributor:

Preventia Healthcare

Marketer:

Ambica
Concise Prescribing Info
Contents
Febuxostat
Indications/Uses
Adults w/ chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus &/or gouty arthritis).
Dosage/Direction for Use
Recommended starting dose is 40 mg once daily. For patients who do not achieve a serum uric acid < 6 mg/dL after 2 wk may increase to 80 mg once daily.
Administration
May be taken with or without food: May be taken w/o regard to antacid use.
Special Precautions
Not recommended in patients w/ ischemic heart disease or CHF. Severe hypersensitivity reactions, including DRESS were associated w/ fever, hematological, renal or hepatic involvement may occur; discontinue immediately if serious allergic/hypersensitivity reactions, including SJS occurs; must not be re-started in this patient at any time. Acute gouty attacks (gout flare). Patients in whom the rate of urate formation is greatly increased (eg, malignant disease & its treatment, Lesch-Nyhan syndrome) the absolute conc of xanthine in urine could rise sufficiently to allow deposition in the urinary tract. Concomitant treatment w/ mercaptopurine/azathioprine. Organ transplant recipients. LFT is recommended prior to the initiation of therapy & periodically thereafter. Patients w/ alteration of thyroid function; may increase TSH values in long-term use. Do not give in patients w/ rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. May affect the ability to drive & use machines. Do not use during pregnancy & while breastfeeding.
Adverse Reactions
Gout flares; headache; diarrhea, nausea; liver function abnormalities; oedema.
Drug Interactions
Concomitant use w/ mercaptopurine/azathioprine may increase plasma conc of mercaptopurine/azathioprine. Increased metabolism & decreased efficacy w/ potent inducers of UGT enzymes. Concomitant ingestion of antacid containing Mg hydroxide & Al hydroxide may delayed absorption & decreased Cmax.
MIMS Class
Hyperuricemia & Gout Preparations
ATC Classification
M04AA03 - febuxostat ; Belongs to the class of preparations inhibiting uric acid production. Used in the treatment of gout.
Presentation/Packing
Form
Febufast 40 FC tab 40 mg
Packing/Price
30's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in